Search Results - "Areberg, Johan"

Clinical benefits and bioequivalence of vortioxetine oral drop solution versus oral tablets by Fagiolini, Andrea, Adair, Michael, Buchberg Petersen, Kamilla, Areberg, Johan, Christensen, Michael Cronquist

“…Background: Vortioxetine is efficacious and well tolerated in patients with major depressive disorder (MDD) and is available as an immediate-release tablet and…”
Get full text

Are self-reported and self-monitored adherence good proxies for reaching relevant plasma concentrations?: Experiences from a study of anti-depressants in healthy volunteers by Larsen, Klaus Groes, Areberg, Johan, Åström, Daniel Oudin

“…Background The use of electronic-based devices to measure and to improve adherence of subjects in clinical trials is increasing. AiCure has developed a mobile…”
Get full text

Does ethnicity impact CYP2D6 genotype–phenotype relationships? by Frederiksen, Trine, Areberg, Johan, Schmidt, Ellen, Stage, Tore Bjerregaard, Brøsen, Kim

“…Polymorphism of the CYP2D6 gene leads to substantial interindividual variability in CYP2D6 enzyme activity. Despite improvements in prediction of CYP2D6…”
Get full text

Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine by Frederiksen, Trine, Areberg, Johan, Schmidt, Ellen, Stage, Tore Bjerregaard, Brøsen, Kim

“…The cytochrome P450 (CYP) 2D6 enzyme exhibits large interindividual differences in metabolic activity. Patients are commonly assigned a CYP2D6 phenotype based…”
Get full text

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions by Chen, Grace, Højer, Astrid-Maria, Areberg, Johan, Nomikos, George

“…Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally…”
Get full text

Population pharmacokinetics of eptinezumab in paediatric patients with migraine and dose selection for phase 3 paediatric migraine studies by Areberg, Johan, Rosen, Monika, Lindsten, Annika, Dragheim, Marianne, Ryding, Janka

“…This population pharmacokinetics (PopPK) analysis of eptinezumab used data from a paediatric study and a prior adult PopPK model to compare eptinezumab…”
Get full text

Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of Brexpiprazole by Frederiksen, Trine, Areberg, Johan, Raoufinia, Arash, Schmidt, Ellen, Stage, Tore Bjerregaard, Brøsen, Kim

“…Accurate prediction of CYP2D6 phenotype from genotype information is important to support safe and efficacious pharmacotherapy with CYP2D6 substrates. To…”
Get full text

Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine by Frederiksen, Trine, Areberg, Johan, Schmidt, Ellen, Bjerregaard Stage, Tore, Brøsen, Kim

“…Assignment of CYP2D6 phenotype from genotype data can be challenging and despite efforts to standardize translation, there is currently no universally accepted…”
Get full text

Antitumor effect of radioactive cisplatin (191Pt) on nude mice by Areberg, J, Wennerberg, J, Johnsson, A, Norrgren, K, Mattsson, S

“…To investigate the effect of (191)Pt-cisplatin in vivo in terms of the antitumor effect and general toxicity on tumor-bearing nude mice. Tumor-bearing (human…”
Get more information

Comparative renal, hepatic, and bone marrow toxicity of Cisplatin and radioactive Cisplatin (191Pt) in Wistar rats by Norrgren, Kristina, Sjölin, Maria, Björkman, Sven, Areberg, Johan, Johnsson, Anders, Johansson, L, Mattsson, Sören

“…The aim of the study was to investigate the possibility to increase the therapeutic gain of the cytotoxic agent, cisplatin, by incorporation of radioactive…”
Get more information

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study by Rancans, Elmars, Zambori, Janos, Dalsgaard, Mads, Baayen, Corine, Areberg, Johan, Ettrup, Anders, Florea, Ioana

“…This 7-day randomized, double-blind, placebo-controlled fixed-dose study (NCT03766867) explored the potential for accelerating the onset of antidepressant…”
Get full text

Accuracy of the quantification of organ activity from planar gamma camera images by Norrgren, Kristina, Svegborn, Sigrid Leide, Areberg, Johan, Mattsson, Sören

“…The accuracy in determination of organ activity of (99m)Tc was investigated, with activity estimated from gamma camera images of phantoms, using the conjugate…”
Get more information

Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data by Frederiksen, Trine, Smith, Robert L., Wollmann, Birgit M., Areberg, Johan, Molden, Espen

“…Introduction Vortioxetine is an antidepressant primarily metabolized by the polymorphic enzyme cytochrome P450 (CYP) 2D6. A population pharmacokinetic (popPK)…”
Get full text

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study by Vieta, Eduard, Florea, Ioana, Schmidt, Simon Nitschky, Areberg, Johan, Ettrup, Anders

“…This 2-week randomized, double-blind, placebo-controlled fixed-dose study (NCT02919501) explored the potential of accelerating onset of antidepressant efficacy…”
Get full text

Stress-free blood sampling in minipigs: A novel method for assessing 24-h cortisol profiles and drug effects on diurnal and ultradian rhythms by Rode, Frederik, Bundgaard, Christoffer, Areberg, Johan, Madsen, Lone Bruhn, Taavoniku, Ida, Hansen, Lene, Weisser, Johan, Olsen, Line Rørbæk, Elgaard, Heidi Toft, Eneberg, Elin, Didriksen, Michael

“…We developed a novel, stress-free blood sampling method for minipigs, allowing continuous cortisol monitoring over 24 h. Baseline cortisol levels exhibited…”
Get full text

Population Pharmacokinetic Meta‐Analysis of Vortioxetine in Healthy Individuals by Areberg, Johan, Petersen, Kamilla B., Chen, Grace, Naik, Himanshu

“…The objective was to describe the pharmacokinetics of vortioxetine and evaluate the effect of intrinsic and extrinsic factors in the healthy population. Data…”
Get full text

The Clinical Pharmacokinetics of Lu AA21004 and its Major Metabolite in Healthy Young Volunteers by Areberg, Johan, Søgaard, Birgitte, Højer, Astrid-Maria

“…Lu AA21004 is a novel multimodal antidepressant that is currently in phase 3 development. The objective of this report was to detail the clinical…”
Get full text

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population by Miao, Jia, Wang, Gang, Hou, Jie, Areberg, Johan, Zhao, Yan, Højer, Astrid-Maria, Ettrup, Anders

“…Introduction Major depressive disorder (MDD) is associated with a significant burden of disease in China. Awareness and better access to treatments could help…”
Get full text

Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ‐opioid receptor occupancy by Kyhl, Lars‐Erik Broksoe, Li, Shen, Faerch, Kirstine Ullitz, Soegaard, Birgitte, Larsen, Frank, Areberg, Johan

“…Aims The aims of this study were to develop a population pharmacokinetic (PK) model to describe the PK of nalmefene in healthy subjects and to relate the…”
Get full text

Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men by Wilson, Sue, Højer, Astrid-Maria, Buchberg, Jeppe, Areberg, Johan, Nutt, David J

“…We compared the effect of vortioxetine, paroxetine and placebo after three days of dosing on sleep architecture. This was a randomised, double-blind, four-way…”
Get full text